Dasapharm Limited Filleted Accounts Cover
Dasapharm Limited
Company No. 09325869
Information for Filing with The Registrar
31 December 2024
Dasapharm Limited Directors Report Registrar
The Directors present their report and the accounts for the year ended 31 December 2024.
Principal activities
The principal activity of the company during the year under review was wholesale pharmaceutical goods.
Directors
The Directors who served at any time during the year were as follows:
A. Katzman
D. Mevzos
The above report has been prepared in accordance with the provisions applicable to companies subject to the small companies regime as set out in Part 15 of the Companies Act 2006.
Signed on behalf of the board
D. Mevzos
Director
09 July 2025
Dasapharm Limited Balance Sheet Registrar
at
31 December 2024
Company No.
09325869
Notes
2024
2023
$
$
Fixed assets
Intangible assets
4
60,615-
Tangible assets
5
-2,032
60,6152,032
Current assets
Stocks
6
1,488,380494,230
Debtors
7
1,148,423987,739
Cash at bank and in hand
2,079,544871,546
4,716,3472,353,515
Creditors: Amount falling due within one year
8
(4,896,923)
(2,487,687)
Net current liabilities
(180,576)
(134,172)
Total assets less current liabilities
(119,961)
(132,140)
Net liabilities
(119,961)
(132,140)
Capital and reserves
Called up share capital
134134
Profit and loss account
10
(120,095)
(132,274)
Total equity
(119,961)
(132,140)
These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime of the Companies Act 2006.
For the year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
As permitted by section 444 (5A)of the Companies Act 2006 the directors have not delivered to the Registrar a copy of the company's profit and loss account.
Approved by the board on 09 July 2025 and signed on its behalf by:
D. Mevzos
Director
09 July 2025
Dasapharm Limited Notes to the Accounts Registrar
for the year ended 31 December 2024
1
General information
Dasapharm Limited is a private company limited by shares and incorporated in England and Wales.
The company's registered number is: 09325869
The address of the company's registered office is:
C/O FKGB
2nd Floor
201 Haverstock Hill
London
NW3 4QG
The accounts have been prepared in accordance with FRS 102 Section 1A - The Financial Reporting Standard applicable in the UK and Republic of Ireland (January 2022) and the Companies Act 2006.
Going concern
These financial statements have been prepared on a going concern basis. The director, having considered the financial position of the company for a period of at least twelve months from the date of signing these financial statements, has no reason to believe that a material uncertainty exists that may cast doubt about the ability of the company to continue as a going concern. Accordingly the director has a reasonable expectation that the company will continue in operational existence and therefore he continues to adopt the going concern basis of accounting to prepare the financial statements.
2
Accounting policies
Turnover
Turnover is measured at the fair value of the consideration received or receivable. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Revenue from the sale of goods is recognised when all the following conditions are satisfied:
• the Company has transferred to the buyer the significant risks and rewards of ownership of the
goods;
• the Company retains neither continuing managerial involvement to the degree usually associated
with ownership nor effective control over the goods sold;
• the amount of revenue can be measured reliably;
• it is probable that the economic benefits associated with the transaction will flow to the Company;
and
• the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Specifically, revenue from the sale of goods is recognised when goods are delivered and legal title is passed.
Intangible fixed assets
Intangible fixed assets are carried at cost less accumulated amortisation and impairment losses.
Tangible fixed assets and depreciation
Tangible fixed assets held for the company's own use are stated at cost less accumulated depreciation and accumulated impairment losses.

At each balance sheet date, the company reviews the carrying amount of its tangible fixed assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss.
Depreciation is provided at the following annual rates in order to write off the cost or valuation less the estimated residual value of each asset over its estimated useful life:
Furniture, fittings and equipment
25% straight line
Research and development costs
In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.
Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the profit and loss account because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Stocks
Stocks are stated at the lower of cost and net realisable value. Net realisable value is based upon estimated selling prices less further costs expected to be incurred to disposal.
At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in the statement of comprehensive income.
Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method, less impairment losses for bad and doubtful debts.
Trade and other creditors
Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
Foreign currencies
The functional and presentational currency of the company is US Dollar. The accounts are rounded to the nearest dollar.
Transactions in currencies, other than the functional currency of the Company, are recorded at the rate of exchange on the date the transaction occurred. Monetary items denominated in other currencies are translated at the rate prevailing at the end of the reporting period. all differences are taken to the profit and loss account. Non-monetary items that are measured at historic cost in a foreign currency are not retranslated.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors including expectations of future events that are believed to be reasonable under the circumstances.
Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable.
Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
Loans and borrowings
Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment.
3
Employees
2024
2023
Number
Number
The average monthly number of employees (including directors) during the year was:
00
4
Intangible fixed assets
Development costs
Total
$
$
Cost
Additions
66,50066,500
At 31 December 2024
66,50066,500
Amortisation and impairment
Charge for the year
5,8855,885
At 31 December 2024
5,8855,885
Net book values
At 31 December 2024
60,61560,615
5
Tangible fixed assets
Fixtures, fittings and equipment
Total
$
$
Cost or revaluation
At 1 January 2024
18,71618,716
At 31 December 2024
18,71618,716
Depreciation
At 1 January 2024
16,68416,684
Charge for the year
2,0322,032
At 31 December 2024
18,71618,716
Net book values
At 31 December 2024
--
At 31 December 2023
2,032
2,032
6
Stocks
2024
2023
$
$
Finished goods
1,488,380494,230
1,488,380494,230
7
Debtors
2024
2023
$
$
Trade debtors
1,112,740979,770
VAT recoverable
6,0073,954
Other debtors
3,4763,476
Prepayments and accrued income
26,200539
1,148,423987,739
8
Creditors:
amounts falling due within one year
2024
2023
$
$
Trade creditors
1,494,781385,216
Amounts owed to group undertakings
1,693,838
1,388,126
Accruals and deferred income
1,708,304714,345
4,896,9232,487,687
9
Share Capital
The company has 100 ordinary share of $1.34 each, amounting to a share capital of $134 (2023: $134).
10
Reserves
Profit and loss account - includes all current and prior period retained profits and losses.
11
Related party disclosures
Transactions with related parties
There was a balance of $1,876,392 (2023: $1,388,126) made up of loans and management fees owed to Dasapharm Ltd (BVI) a company with a common Director.
Dasapharm Limited0932586931 December 202401 January 2024false09 July 2025BTCSoftware AP Solution 2025 12.1.0312.1.03true093258692024-01-012024-12-31093258692024-12-31093258692023-12-3109325869core:WithinOneYear2024-12-3109325869core:WithinOneYear2023-12-3109325869core:ShareCapital2024-12-3109325869core:ShareCapital2023-12-3109325869core:RetainedEarningsAccumulatedLosses2024-12-3109325869core:RetainedEarningsAccumulatedLosses2023-12-3109325869countries:UnitedKingdom2024-01-012024-12-3109325869bus:RegisteredOffice2024-01-012024-12-3109325869core:FurnitureFittingsToolsEquipment2024-01-012024-12-31093258692023-01-012023-12-3109325869core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-01-012024-12-3109325869core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-3109325869core:FurnitureFittingsToolsEquipment2024-01-01093258692024-01-0109325869core:FurnitureFittingsToolsEquipment2024-12-3109325869core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3109325869bus:SmallEntities2024-01-012024-12-3109325869bus:FullAccounts2024-01-012024-12-3109325869bus:AuditExempt-NoAccountantsReport2024-01-012024-12-3109325869bus:Director22024-01-012024-12-3109325869bus:PrivateLimitedCompanyLtd2024-01-012024-12-31iso4217:USDxbrli:pure